Association of Long-Term 5α-Reductase Inhibitor Use With Survival in Men With Renal Cell Carcinoma: A Nationwide Population-Based Cohort Study

    May 2026 in “ Frontiers in Pharmacology ”
    Sieun Lee, Jooyoung Lee, Kyungchan Min, Jong Hyun Tae, Chung Un Lee, Joongwon Choi, Jae‐Joong Kim, Y N Lee, T U O N G Nguyen, Se Young Choi
    Image of study
    TLDR Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
    This study investigated the impact of long-term 5α-reductase inhibitor (5-ARI) use on survival in men with renal cell carcinoma (RCC) using data from 31,927 men in Korea. The study found that long-term use of 5-ARIs, such as finasteride or dutasteride, was associated with significantly lower all-cause mortality, particularly in patients who did not undergo surgery or systemic therapy and had low comorbidity. The results suggest that androgen modulation through 5-ARIs may positively influence RCC progression, indicating potential for these inhibitors as adjunctive treatments in specific clinical scenarios.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results